"Bladder cancer originates generally in the inner lining of bladder and its first sign generally is presence of blood in urine. Bladder cancer is initially treated with transurethral resection, or TUR. However, the key problem with treatment is recurrence of the disease. Based on scientific literature, 75% of all patients have a recurrence within 5 years; several of these patients have multiple recurrences. Repeated cystoscopes are needed because of the high recurrence of the disease in previous patients. Because this cancer is nonfatal, and because there is a high incidence and recurrence, bladder cancer is one of the most expensive cancers to treat.
• In the US, each year there are 68,810 new cases of bladder cancer, of which approximately 70% to 80% of patients will present with non-invasive bladder tumors. In the United States and Europe, there are around 522,000 and 944,000 bladder cancer patients, respectively. FEW ALTERNATIVES are available for bladder cancer patients and new drugs for it were LAST APPROVED in 1975. Based on the size of this market, and the need arising due to recurrences, a drug that could lower the recurrence rate could potentially be a BLOCKBUSTER DRUG."